Francisco J. Esteva, Chief of the Division of Hematology and Medical Oncology at Lenox Hill Hospital, shared a post on LinkedIn:
“2026 Breast Cancer Trials That Will Change Practice.
Not every clinical trial changes what we do in the clinic. Most add knowledge. A few force us to rethink decisions.
This carousel highlights five studies presented at recent meetings that are already reshaping how clinicians think about first-line therapy, maintenance strategies, endocrine resistance, and molecular monitoring across breast cancer subtypes.
Together, they reflect a clear shift toward earlier use of more effective agents, smarter sequencing, and treatment decisions guided by biology rather than chronology.
What stands out is not just improved outcomes, but how those outcomes are achieved: antibody–drug conjugates moving earlier, maintenance therapy becoming active rather than passive, oral SERDs challenging long-standing standards, and liquid biopsy guiding treatment changes before clinical progression occurs.
See how DESTINY-Breast09, HER2CLIMB-05, lidERA, ASCENT-04, and SERENA-6 may influence real-world practice in 2026 and beyond.
Which of these trials do you think will change practice first?”
More posts featuring Francisco J. Esteva.